Key Events This Week
20 Jul: Stock opens at Rs.1,023.95 with marginal gain
21 Jul: Downgrade to Sell announced; stock drops 2.78%
22 Jul: Technical momentum shift highlighted; stock declines further
24 Jul: Week closes at Rs.962.00, down 0.91% on the day
Monday, 20 July 2026: Modest Start Amid Market Stability
Jubilant Pharmova commenced the week at Rs.1,023.95, registering a slight gain of 0.17% on the day. This marginal increase came despite the Sensex closing nearly flat at 36,504.94, down 0.00%. Trading volume was relatively low at 4,307 shares, reflecting subdued investor activity ahead of the week’s key developments. The stock remained well below its 52-week high of Rs.1,250.00, indicating limited upward momentum at the outset.
Tuesday, 21 July 2026: Downgrade Sparks Sharp Decline
The pivotal event of the week occurred on 21 July when MarketsMOJO downgraded Jubilant Pharmova Ltd from a 'Hold' to a 'Sell' rating. This decision was driven by a combination of deteriorating technical indicators and flat financial performance, signalling caution to investors. The downgrade was accompanied by a drop in the stock price to Rs.995.45, a decline of 2.78% from the previous close. Volume increased slightly to 4,757 shares, reflecting heightened trading activity amid the negative sentiment.
The downgrade highlighted several concerns: a shift in technical momentum from mildly bullish to mildly bearish, flat quarterly financial results with a 15.91% quarter-on-quarter decline in profit before tax excluding other income, and a 17.5% fall in profit after tax. Despite trading at a valuation discount relative to peers, these fundamental weaknesses weighed heavily on the stock.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Wednesday, 22 July 2026: Technical Momentum Shift Deepens
On 22 July, the stock price further declined to Rs.993.10, down 0.24% from the previous day, with volume surging to 8,278 shares. This day marked a significant technical shift as the stock moved from a mildly bullish to a mildly bearish trend. Key indicators such as the monthly Moving Average Convergence Divergence (MACD) turned bearish, while weekly MACD remained bullish, signalling a complex and transitional technical landscape.
The Relative Strength Index (RSI) hovered in neutral territory, and Bollinger Bands showed a mildly bullish stance weekly but mildly bearish monthly. Daily moving averages turned mildly bearish, reinforcing short-term weakness. The Know Sure Thing (KST) indicator and Dow Theory presented mixed signals, with weekly optimism offset by monthly caution. This nuanced technical picture contributed to the stock’s continued downward pressure amid broader sector headwinds.
Thursday, 23 July 2026: Continued Decline Amid Market Weakness
Jubilant Pharmova’s stock price dropped further to Rs.970.85, a 2.24% decline on the day, with volume at 4,974 shares. The Sensex also weakened, closing at 35,944.66, down 0.70%. The stock’s decline aligned with the broader market sell-off but was more pronounced, reflecting the lingering impact of the downgrade and technical concerns. The stock remained above its 52-week low of Rs.783.75 but showed no signs of stabilising as investor sentiment remained cautious.
Friday, 24 July 2026: Week Ends on a Soft Note
The week concluded with Jubilant Pharmova closing at Rs.962.00, down 0.91% on the day, with increased volume of 6,950 shares. The Sensex also declined by 0.32% to 35,829.46. The stock’s weekly performance of -5.89% significantly underperformed the Sensex’s -1.85%, underscoring the stock-specific challenges faced. The technical indicators and fundamental concerns that emerged earlier in the week continued to weigh on the stock’s price action.
Considering Jubilant Pharmova Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
Daily Price Comparison: Jubilant Pharmova vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-07-20 | Rs.1,023.95 | +0.17% | 36,504.94 | -0.00% |
| 2026-07-21 | Rs.995.45 | -2.78% | 36,518.28 | +0.04% |
| 2026-07-22 | Rs.993.10 | -0.24% | 36,196.43 | -0.88% |
| 2026-07-23 | Rs.970.85 | -2.24% | 35,944.66 | -0.70% |
| 2026-07-24 | Rs.962.00 | -0.91% | 35,829.46 | -0.32% |
Key Takeaways
Technical Deterioration: The downgrade to a 'Sell' rating was underpinned by a shift in technical momentum from mildly bullish to mildly bearish, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages. This suggests increased downside risk and volatility in the near term.
Financial Performance Concerns: Flat quarterly results with a 15.91% decline in profit before tax and a 17.5% drop in profit after tax highlight operational challenges. The negative five-year operating profit trend of -8.03% annualised further undermines confidence.
Valuation vs Fundamentals: Although the stock trades at a valuation discount with a ROCE of 8.7% and an EV/CE ratio of 1.9, these metrics do not offset the deteriorating fundamentals and weak earnings trajectory.
Underperformance Relative to Market: The stock’s 5.89% weekly decline significantly outpaced the Sensex’s 1.85% fall, reflecting stock-specific pressures beyond broader market weakness.
Long-Term Returns Remain Robust: Despite recent weakness, Jubilant Pharmova’s three-year and ten-year returns of 166.52% and 208.24% respectively, substantially outperform the Sensex, indicating strong historical growth.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
Conclusion
Jubilant Pharmova Ltd’s week was dominated by a significant downgrade and a shift in technical momentum that collectively pressured the stock price down by 5.89%. The downgrade to 'Sell' by MarketsMOJO reflects a comprehensive reassessment of the company’s risk profile, driven by flat financial results, weakening technical indicators, and subdued near-term growth prospects. While the stock’s valuation remains attractive relative to peers, this alone does not compensate for the deteriorating fundamentals and increased volatility. Investors should note the divergence between the company’s strong long-term returns and its recent underperformance, signalling a period of caution amid evolving market dynamics. The stock’s performance this week underscores the importance of monitoring both technical signals and fundamental trends in assessing investment prospects.
